Loading...

Invitae

NYSE:NVTA
Snowflake Description

High growth potential with excellent balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
NVTA
NYSE
$2B
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Invitae Corporation, a genetic information company, processes DNA-containing samples, analyzes information related to patient-specific genetic variation, and generates test reports for clinicians and their patients in the United States, Canada, and internationally. The last earnings update was 77 days ago. More info.


Add to Portfolio Compare Print
  • Invitae has significant price volatility in the past 3 months.
NVTA Share Price and Events
7 Day Returns
8.7%
NYSE:NVTA
-1%
US Biotechs
-1.2%
US Market
1 Year Returns
184.3%
NYSE:NVTA
-11.9%
US Biotechs
3.3%
US Market
NVTA Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Invitae (NVTA) 8.7% 13.6% 4.2% 184.3% 199.3% -
US Biotechs -1% -3.6% -0.7% -11.9% 5.4% 7.4%
US Market -1.2% 0.8% 0.9% 3.3% 35.9% 41.7%
1 Year Return vs Industry and Market
  • NVTA outperformed the Biotechs industry which returned -11.9% over the past year.
  • NVTA outperformed the Market in United States of America which returned 3.3% over the past year.
Price Volatility
NVTA
Industry
5yr Volatility vs Market

NVTA Value

 Is Invitae undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Invitae. This is due to cash flow or dividend data being unavailable. The share price is $24.48.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Invitae's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Invitae's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NYSE:NVTA PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in USD $-1.79
NYSE:NVTA Share Price ** NYSE (2019-07-22) in USD $24.48
United States of America Biotechs Industry PE Ratio Median Figure of 35 Publicly-Listed Biotechs Companies 19.44x
United States of America Market PE Ratio Median Figure of 3,082 Publicly-Listed Companies 17.86x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Invitae.

NYSE:NVTA PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NYSE:NVTA Share Price ÷ EPS (both in USD)

= 24.48 ÷ -1.79

-13.65x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Invitae is loss making, we can't compare its value to the US Biotechs industry average.
  • Invitae is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Invitae's expected growth come at a high price?
Raw Data
NYSE:NVTA PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -13.65x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 8 Analysts
39.2%per year
United States of America Biotechs Industry PEG Ratio Median Figure of 26 Publicly-Listed Biotechs Companies 0.79x
United States of America Market PEG Ratio Median Figure of 2,119 Publicly-Listed Companies 1.57x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Invitae, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Invitae's assets?
Raw Data
NYSE:NVTA PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in USD $3.53
NYSE:NVTA Share Price * NYSE (2019-07-22) in USD $24.48
United States of America Biotechs Industry PB Ratio Median Figure of 437 Publicly-Listed Biotechs Companies 2.93x
United States of America Market PB Ratio Median Figure of 5,248 Publicly-Listed Companies 1.79x
NYSE:NVTA PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NYSE:NVTA Share Price ÷ Book Value per Share (both in USD)

= 24.48 ÷ 3.53

6.93x

* Primary Listing of Invitae.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Invitae is overvalued based on assets compared to the US Biotechs industry average.
X
Value checks
We assess Invitae's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Invitae has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

NVTA Future Performance

 How is Invitae expected to perform in the next 1 to 3 years based on estimates from 8 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
39.2%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Invitae expected to grow at an attractive rate?
  • Invitae's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Growth vs Market Checks
  • Invitae's earnings growth is expected to exceed the United States of America market average.
  • Invitae's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NYSE:NVTA Future Growth Rates Data Sources
Data Point Source Value (per year)
NYSE:NVTA Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 8 Analysts 39.2%
NYSE:NVTA Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 8 Analysts 31.6%
United States of America Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 23%
United States of America Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 18.5%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 14%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.4%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NYSE:NVTA Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 8 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NYSE:NVTA Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 811 19 2
2022-12-31 632 -51 2
2021-12-31 463 -15 -99 5
2020-12-31 336 -115 -144 8
2019-12-31 221 -127 -169 8
NYSE:NVTA Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-03-31 161 -88 -131
2018-12-31 148 -92 -129
2018-09-30 128 -108 -140
2018-06-30 109 -115 -136
2018-03-31 86 -109 -133
2017-12-31 68 -98 -123
2017-09-30 52 -84 -108
2017-06-30 40 -76 -105
2017-03-31 31 -74 -102
2016-12-31 25 -76 -100
2016-09-30 19 -80 -100
2016-06-30 15 -85 -97

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Invitae's earnings are expected to grow significantly at over 20% yearly.
  • Invitae's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NYSE:NVTA Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 8 Analyst Estimates (S&P Global) See Below

All data from Invitae Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NYSE:NVTA Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 0.18 0.36 0.00 2.00
2022-12-31 -0.52 -0.51 -0.52 2.00
2021-12-31 -0.98 -0.72 -1.26 5.00
2020-12-31 -1.45 -0.80 -1.86 7.00
2019-12-31 -1.90 -1.63 -2.26 7.00
NYSE:NVTA Past Financials Data
Date (Data in USD Millions) EPS *
2019-03-31 -1.79
2018-12-31 -1.94
2018-09-30 -2.29
2018-06-30 -2.44
2018-03-31 -2.68
2017-12-31 -2.65
2017-09-30 -2.53
2017-06-30 -2.73
2017-03-31 -2.84
2016-12-31 -3.02
2016-09-30 -3.11
2016-06-30 -3.04

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Invitae will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess Invitae's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Invitae has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

NVTA Past Performance

  How has Invitae performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Invitae's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Invitae does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Invitae's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Invitae's 1-year growth to the US Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Invitae's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Invitae Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NYSE:NVTA Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 160.58 -130.91 129.32 66.12
2018-12-31 147.70 -129.36 122.51 63.50
2018-09-30 127.74 -140.01 120.76 60.53
2018-06-30 108.52 -135.69 114.25 56.26
2018-03-31 85.55 -132.57 103.83 51.81
2017-12-31 68.22 -123.38 91.29 46.47
2017-09-30 52.06 -107.74 77.39 44.64
2017-06-30 40.19 -105.30 65.10 44.62
2017-03-31 31.43 -101.59 57.29 43.99
2016-12-31 25.05 -100.26 51.72 44.63
2016-09-30 18.97 -99.77 48.15 44.24
2016-06-30 14.88 -97.32 45.25 43.89
2016-03-31 11.10 -96.74 42.94 45.01
2015-12-31 8.38 -89.78 38.53 42.81
2015-09-30 6.09 -80.73 35.29 37.89
2015-06-30 4.22 -70.82 31.34 32.31
2015-03-31 2.72 -57.10 25.89 25.55
2014-12-31 1.60 -47.49 21.27 22.06
2014-09-30 0.82 -40.32 16.49 21.02
2014-06-30 0.56 -34.75 13.31 19.92
2014-03-31 0.26 -29.12 10.14 17.92
2013-12-31 0.15 -24.99 8.20 16.04
2012-12-31 -9.01 3.00 5.56

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Invitae has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Invitae has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Invitae improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Invitae's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Invitae has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

NVTA Health

 How is Invitae's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Invitae's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Invitae is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Invitae's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Invitae's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 4.1x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Invitae Company Filings, last reported 3 months ago.

NYSE:NVTA Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 316.41 74.83 281.22
2018-12-31 161.84 74.48 125.89
2018-09-30 179.40 58.49 129.18
2018-06-30 138.65 58.64 85.14
2018-03-31 101.96 58.55 54.97
2017-12-31 121.79 39.08 64.66
2017-09-30 125.39 39.03 76.91
2017-06-30 67.16 38.98 75.37
2017-03-31 82.30 38.92 96.78
2016-12-31 99.07 12.10 92.62
2016-09-30 70.84 12.95 66.75
2016-06-30 92.69 11.13 85.29
2016-03-31 114.51 9.15 103.87
2015-12-31 138.38 7.04 127.02
2015-09-30 161.10 4.79 147.25
2015-06-30 182.65 0.00 170.93
2015-03-31 206.36 0.00 184.33
2014-12-31 118.73 0.00 107.03
2014-09-30 65.14 0.00 59.14
2014-06-30 30.19 0.00 22.04
2014-03-31 49.29 2.00 43.07
2013-12-31 49.29 0.00 43.07
2012-12-31 24.00 0.00 21.80
  • Invitae's level of debt (24.5%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (4.1% vs 24.5% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Invitae has sufficient cash runway for more than 3 years based on current free cash flow.
  • Invitae has sufficient cash runway for 2.8 years if free cash flow continues to grow at historical rates of 7.3% each year.
X
Financial health checks
We assess Invitae's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Invitae has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

NVTA Dividends

 What is Invitae's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Invitae dividends.
If you bought $2,000 of Invitae shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Invitae's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Invitae's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NYSE:NVTA Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 8 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 18 Stocks 2.3%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2017 Stocks 2.4%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.4%
United States of America Top 25% Dividend Yield 75th Percentile 3.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NYSE:NVTA Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Invitae has not reported any payouts.
  • Unable to verify if Invitae's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Invitae's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Invitae has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Invitae's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Invitae afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Invitae has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

NVTA Management

 What is the CEO of Invitae's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Sean George
COMPENSATION $2,233,360
AGE 45
TENURE AS CEO 2.5 years
CEO Bio

Dr. Sean E. George, Ph.D. is the Co-Founder of InVitae Corporation and has been its President since August 2012. Dr. George has been Chief Executive Officer of InVitae Corporation since January 9, 2017 and served as its Chief Operating Officer since August 2008 until January 9, 2017. He has held a number of executive management positions in the life science industry. He served as Chief Operating Officer of Navigenics, Inc. since 2007 until November 2009. He was Co-Founder and Chief Executive Officer of Locus Development Inc. Dr. George served as the President at Locus Development Inc. Dr. George served at Affymetrix, Inc., as Senior Vice President of Marketing, responsible for its marketing, corporate communications, product management, and CRM divisions. He served as Senior Vice President, Life Science Business at Affymetrix. Dr. George served as vice president of life science research at Affymetrix. Dr. George served at Invitrogen, Inc., as vice president of diagnostic solutions, managing its anatomical pathology diagnostic business and driving business to diagnostic and other tools companies. He served as Vice President, Labeling and Detection Business at Invitrogen. Dr. George was strategic planning director of Molecular Probes. Dr. George served as an associate at McKinsey & Company, where he served with various clients in the pharmaceutical and biotech and corporate finance practices. He has been a Director of InVitae Corporation since January 2010. He serves as Member of Scientific advisory board at Genia Technologies, Inc. (alternate name, Genia Corporation). He served as Director at Locus Development Inc. Dr. George received his B.S. in microbiology and molecular genetics from the University of California, Los Angeles, his M.S. in molecular biology from the University of California, Santa Barbara and his Ph.D. in molecular genetics from the University of California, Santa Cruz.

CEO Compensation
  • Sean's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Sean's remuneration is lower than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Invitae management team in years:

2.5
Average Tenure
59
Average Age
  • The tenure for the Invitae management team is about average.
Management Team

Sean George

TITLE
Co-Founder
COMPENSATION
$2M
AGE
45
TENURE
2.5 yrs

Lee Bendekgey

TITLE
Secretary & COO
COMPENSATION
$1M
AGE
61
TENURE
2.1 yrs

Katherine Stueland

TITLE
Chief Commercial Officer
COMPENSATION
$1M
AGE
43
TENURE
2.8 yrs

Randy Scott

TITLE
Executive Chairman
COMPENSATION
$322K
AGE
61
TENURE
2.5 yrs

Shelly Guyer

TITLE
Chief Financial Officer
COMPENSATION
$1M
AGE
59
TENURE
2.1 yrs

Laura D'Angelo

TITLE
Head of Investor Relations

Tom Brida

TITLE
General Counsel
AGE
48
TENURE
2.5 yrs

Robert Nussbaum

TITLE
Chief Medical Officer
COMPENSATION
$803K
AGE
69
TENURE
3.9 yrs

Eric Olivares

TITLE
Head of Clinical Operations & Assay Development
TENURE
2.4 yrs

Alex Furman

TITLE
Executive Officer of Organizational Development
TENURE
1.2 yrs
Board of Directors Tenure

Average tenure and age of the Invitae board of directors in years:

7.1
Average Tenure
56
Average Age
  • The tenure for the Invitae board of directors is about average.
Board of Directors

Sean George

TITLE
Co-Founder
COMPENSATION
$2M
AGE
45
TENURE
9.5 yrs

Randy Scott

TITLE
Executive Chairman
COMPENSATION
$322K
AGE
61
TENURE
6.9 yrs

Eric Aguiar

TITLE
Independent Director
COMPENSATION
$96K
AGE
57
TENURE
8.8 yrs

Geoff Crouse

TITLE
Independent Director
COMPENSATION
$96K
AGE
48
TENURE
7.3 yrs

Christine Gorjanc

TITLE
Independent Director
COMPENSATION
$91K
AGE
62
TENURE
3.7 yrs

Elizabeth McNally

TITLE
Member of Advisory Board

Chitra Nayak

TITLE
Independent Director
COMPENSATION
$165K
AGE
55
TENURE
0.8 yrs
Who owns this company?
Recent Insider Trading
  • Invitae individual insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
23. May 19 Sell Katherine Stueland Individual 20. May 19 20. May 19 -6,474 $18.21 $-117,892
23. May 19 Sell Lee Bendekgey Individual 20. May 19 20. May 19 -6,851 $18.21 $-124,757
23. May 19 Sell Sean George Individual 20. May 19 20. May 19 -24,282 $18.21 $-442,175
23. May 19 Sell Thomas Brida Individual 20. May 19 20. May 19 -2,146 $18.21 $-39,079
22. May 19 Sell Shelly Guyer Individual 20. May 19 20. May 19 -5,513 $18.21 $-100,392
22. May 19 Sell Robert Nussbaum Individual 20. May 19 20. May 19 -7,202 $18.21 $-131,148
18. Apr 19 Sell Katherine Stueland Individual 16. Apr 19 16. Apr 19 -1,000 $25.23 $-25,230
29. Nov 18 Sell Eric Aguiar Individual 27. Nov 18 27. Nov 18 -10,000 $13.50 $-135,000
20. Sep 18 Sell Patricia Dumond Individual 18. Sep 18 20. Sep 18 -645 $16.67 $-10,695
12. Sep 18 Sell Katherine Stueland Individual 09. Sep 18 09. Sep 18 -595 $13.62 $-8,104
X
Management checks
We assess Invitae's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Invitae has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

NVTA News

Simply Wall St News

Could Invitae Corporation's (NYSE:NVTA) Investor Composition Influence The Stock Price?

Taking a look at our data on the ownership groups (below), it's seems that institutional investors have bought into the company. … View our latest analysis for Invitae NYSE:NVTA Ownership Summary, July 10th 2019 What Does The Institutional Ownership Tell Us About Invitae? … Insider Ownership Of Invitae While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders.

Simply Wall St -

Have Insiders Been Selling Invitae Corporation (NYSE:NVTA) Shares?

So we'll take a look at whether insiders have been buying or selling shares in Invitae Corporation (NYSE:NVTA). … As Peter Lynch said, 'insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.' View our latest analysis for Invitae Invitae Insider Transactions Over The Last Year Over the last year, we can see that the biggest insider sale was by the Co-Founder, Sean George, for US$442k worth of shares, at about US$18.21 per share. … Insiders sold Invitae shares recently, but they didn't buy any.

Simply Wall St -

Imagine Holding Invitae (NYSE:NVTA) Shares While The Price Zoomed 327% Higher

For example, the Invitae Corporation (NYSE:NVTA) share price rocketed moonwards 327% in just one year. … But the share price has really rocketed in response gaining 327% as previously mentioned. … But if the share price does moderate a bit, there might be an opportunity for high growth investors.

Simply Wall St -

Do Institutions Own Invitae Corporation (NYSE:NVTA) Shares?

Every investor in Invitae Corporation (NYSE:NVTA) should be aware of the most powerful shareholder groups. … With a market capitalization of US$2.0b, Invitae is a decent size, so it is probably on the radar of institutional investors. … Taking a look at our data on the ownership groups (below), it's seems that.

Simply Wall St -

Invitae Corporation (NYSE:NVTA): What's The Analyst Consensus Outlook?

Invitae Corporation's (NYSE:NVTA) most recent earnings announcement in December 2018 … company earnings became less negative compared to the previous year's level

Simply Wall St -

Are Insiders Selling Invitae Corporation (NYSE:NVTA) Stock?

We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. … So before you buy or sell Invitae Corporation (NYSE:NVTA), you may well want to know whether insiders have been buying or selling. … But logic dictates you should pay some attention to whether insiders are buying or selling shares.

Simply Wall St -

Invitae Corporation (NYSE:NVTA): Is Healthcare An Attractive Sector Play?

operates in the healthcare industry, … The growth in development of new drugs for unmet needs, as well as the ongoing and increasing need for biotech drugs as Baby Boomer generation continues to age, are growth drivers for the positive outlook in the biotech industry over the long term … Healthcare analysts are forecasting for the entire industry,

Simply Wall St -

Before You Buy Invitae Corporation's (NYSE:NVTA), Consider This

The other type of risk, which cannot be diversified away, is market risk. … Every stock in the market is exposed to this risk, which arises from macroeconomic factors such as economic growth and geo-political tussles just to name a few. … The most widely used metric to quantify a stock's market risk is beta, and the market as a whole represents a beta of one.

Simply Wall St -

March Top Growth Stocks To Buy

Its expected double-digit top-line and bottom-line growth exceeds its peers, and its financially stable position lessens the chances of risk. … Furthermore, the high growth of over 100% in operating cash flows indicates that a large portion of this earnings increase is high-quality, day-to-day cash generated by the business, rather than one-offs. … NasdaqGS:WIX Future Profit Mar 18th 18 For more financially robust companies with high growth potential to enhance your portfolio, explore this interactive list of fast growing companies.

Simply Wall St -

Where Invitae Corporation (NYSE:NVTA) Stands In Terms Of Earnings Growth Against Its Industry

See our latest analysis for Invitae Was NVTA's recent earnings decline worse than the long-term trend and the industry? … I prefer to use data from the most recent 12 months, which annualizes the most recent half-year data, or in some cases, the latest annual report is already the most recent financial year data. … Each year, for the past five years Invitae's top-line has grown by 88.76% on average, signalling that the company is in a high-growth phase with expenses racing ahead revenues, leading to annual losses.

Simply Wall St -

NVTA Company Info

Description

Invitae Corporation, a genetic information company, processes DNA-containing samples, analyzes information related to patient-specific genetic variation, and generates test reports for clinicians and their patients in the United States, Canada, and internationally. Its tests include genes associated with hereditary cancer, neurological disorders, cardiovascular disorders, pediatric disorders, metabolic disorders, and other hereditary conditions; and screening and testing services in reproductive health, including preimplantation and carrier screening for inherited disorders, prenatal diagnosis, miscarriage analysis, and pediatric developmental disorders. The company also operates AltaVoice, a platform for collecting, curating, coordinating, and delivering data from patients and clinicians; and CancerGene Connect, an end-to-end platform for collecting and managing genetic family histories to deliver personalized genetic risk information. It serves patients, healthcare providers, and biopharma and advocacy partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was founded in 2010 and is headquartered in San Francisco, California.

Details
Name: Invitae Corporation
NVTA
Exchange: NYSE
Founded: 2010
$2,293,900,921
93,705,103
Website: http://www.invitae.com
Address: Invitae Corporation
1400 16th Street,
San Francisco,
California, 94103,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NYSE NVTA Common Stock New York Stock Exchange US USD 12. Feb 2015
DB IV8 Common Stock Deutsche Boerse AG DE EUR 12. Feb 2015
LSE 0JDB Common Stock London Stock Exchange GB USD 12. Feb 2015
Number of employees
Current staff
Staff numbers
884
Invitae employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/07/23 01:02
End of day share price update: 2019/07/22 00:00
Last estimates confirmation: 2019/07/12
Last earnings filing: 2019/05/07
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.